A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

Inclusion Criteria: All * Be a man or woman 18 to 79 years of age, inclusive Participants with normal hepatic function * Generally healthy * Must not exceed upper limit of normal limits for serum bilirubin, transaminase levels, albumin levels, prothrombin time (PT), and International Normalized Ratio (INR) when measured at screening and Day 1 Participants with (Mild, Moderate or Severe) hepatic impairment * Medically stable * Total Child-Pugh score of 5 or 6, inclusive (mild); or 7 to 9, inclusive (moderate); or 10 to 15, inclusive (severe) as determined by the investigator * Stable hepatic function during screening and those measured on Day 1 * Stable renal function Exclusion Criteria: Participants with normal hepatic function * Hepatitis B surface antigen (HBsAg) or hepatitis C antibodies at screening Participants with (Mild, Moderate or Severe) hepatic impairment * Severe ascites or pleural effusion; prothrombin time greater than (\>)18 seconds; evidence of progressive liver disease within the previous 4 weeks, as indicated by changes in hepatic transaminases, alkaline phosphatase, and gamma-glutamyl transferase * History of hepatopulmonary syndrome, hydrothorax, or significant hepatorenal syndrome * Acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment in the judgment of either the investigator or the sponsor's medical monitor * Clinically significant laboratory findings except as related to hepatic impairment